Close Menu
Home » Palmetto Issues Final LCD for Decipher Biosciences Prostate Cancer Test

Palmetto Issues Final LCD for Decipher Biosciences Prostate Cancer Test

Dec 03, 2019
|
staff reporter

NEW YORK – Decipher Biosciences announced on Tuesday that Medicare Administrative Contractor Palmetto GBA has issued a final local coverage determination (LCD) for the use of the company's Decipher Prostate Biopsy test in men diagnosed with favorable or unfavorable intermediate-risk prostate cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Letting Samples Fly

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Layoffs at 23andMe

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Dusty Resistance

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

Science Studies Use Single-Cell RNA Sequencing to Study Cell States, Apply Deep Phenotyping to Pregnancy

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more. 

What's Popular?

In Business News

  1. 23andMe Lays off 100 Employees Across Consumer Business

  2. 10x Genomics Lawsuit Over Exclusivity of Harvard Single-Cell IP License Going to Trial

  3. Adaptive Biotechnologies Prices Public Offering of Stock

  4. Federal Court Whittles Down Fluidigm Lawsuit Against IonPath

  5. Quest Diagnostics Acquires Blueprint Genetics

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.